In this week’s podcast, Neurology Today’s editor-in-chief highlights articles on proposed updated criteria for diagnosing MS before symptoms manifest, the use of large language models to address administrative burden with electronic medical records, and the growth of training programs in neonatal neurocritical care.

<description>&lt;p&gt;&lt;span style= "font-size: 10.0pt; line-height: 115%; font-family: 'Trebuchet MS',sans-serif; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt; In this week’s podcast, &lt;em&gt;Neurology Today&lt;/em&gt;’s editor-in-chief highlights articles on proposed updated criteria for diagnosing MS before symptoms manifest, the use of large language models to address administrative burden with electronic medical records, and the growth of training programs in neonatal neurocritical care.&lt;/span&gt;&lt;/p&gt;</description>

Revised criteria for diagnosing MS, AI for alleviating administrative burden, neonatal neurocritical care as a growing subspecialty

In this week’s podcast, Neurology Today’s editor-in-chief highlights articles on proposed updated criteria for diagnosing MS before symptoms manifest, the use of large language models to address administrative burden with electronic medical records, and the growth of training programs in neonatal neurocritical care.

In this week’s podcast, Neurology Today’s editor-in-chief highlights articles on a study highlighting three-year outcomes for patients with anti-NMDAR encephalitis, an analysis comparing the diagnostic efficacy of skin biopsies vs. CSF tests for human prion diseases, and the ways in which a graduate degree in public health and/or business administration can shape career pathways for neurologists.

<description>&lt;p&gt;&lt;span style= "font-size: 10.0pt; line-height: 115%; font-family: 'Trebuchet MS',sans-serif; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt; In this week’s podcast, &lt;em&gt;Neurology Today&lt;/em&gt;’s editor-in-chief highlights articles on a study highlighting three-year outcomes for patients with anti-NMDAR encephalitis, an analysis comparing the diagnostic efficacy of skin biopsies vs. CSF tests for human prion diseases, and the ways in which a graduate degree in public health and/or business administration can shape career pathways for neurologists. &lt;span style= "mso-spacerun: yes;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</description>

3-year outcomes for anti-NMDAR encephalitis, skin biopsies for diagnosis of human prion diseases, the career benefits of graduate degrees in public health and/or business administration

In this week’s podcast, Neurology Today’s editor-in-chief highlights articles on a study highlighting three-year outcomes for patients with anti-NMDAR encephalitis, an analysis comparing the diagnostic efficacy of skin biopsies vs. CSF tests for human prion diseases, and the ways in which a graduate degree in public health and/or business administration can shape career pathways for neurologists.  

In this week’s podcast, Neurology Today’s editor-in-chief highlights articles on the higher risk for cardiovascular effects with certain antiseizure therapies on adults with epilepsy, the impact of social determinants of health on children with MS, and the status of coverage for blood-based tests for Alzheimer’s disease.

<description>&lt;p&gt;&lt;span style= "font-size: 10.0pt; line-height: 115%; font-family: 'Trebuchet MS',sans-serif; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt; In this week’s podcast, &lt;em&gt;Neurology Today&lt;/em&gt;’s editor-in-chief highlights articles on the higher risk for cardiovascular effects with certain antiseizure therapies on adults with epilepsy, the impact of social determinants of health on children with MS, and the status of coverage for blood-based tests for Alzheimer’s disease.&lt;/span&gt;&lt;/p&gt;</description>

Cardiovascular effects of antiseizure therapies, social determinants of health on children with MS, coverage for blood-based biomarkers for Alzheimer’s

In this week’s podcast, Neurology Today’s editor-in-chief highlights articles on the higher risk for cardiovascular effects with certain antiseizure therapies on adults with epilepsy, the impact of social determinants of health on children with MS, and the status of coverage for blood-based tests for Alzheimer’s disease.

In this week’s podcast, Neurology Today’s editor-in-chief highlights articles on fever prevention and stroke outcomes, the impact of air pollution and other environmental toxins on Parkinson’s, and the role of cholesterol overload in ALS progression and disease risk.

<description>&lt;p&gt;&lt;span style= "font-size: 10.0pt; line-height: 115%; font-family: 'Trebuchet MS',sans-serif; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt; In this week’s podcast, &lt;em&gt;Neurology Today&lt;/em&gt;’s editor-in-chief highlights articles on fever prevention and stroke outcomes, the impact of air pollution and other environmental toxins on Parkinson’s, and the role of cholesterol overload in ALS progression and disease risk.&lt;/span&gt;&lt;/p&gt;</description>

Fever prevention and stroke, environmental toxins and Parkinson’s, cholesterol overload and ALS progression

In this week’s podcast, Neurology Today’s editor-in-chief highlights articles on fever prevention and stroke outcomes, the impact of air pollution and other environmental toxins on Parkinson’s, and the role of cholesterol overload in ALS progression and disease risk.

In this week’s podcast, Neurology Today’s editor-in-chief highlights articles on the potential of a new blood biomarker for ALS, a PACP-targeted migraine therapy, and a real-world review of data on eculizumab for neuromyelitis optica spectrum disorder. This Podcast is being Sponsored by LocumTenens.com

<description>&lt;p&gt;&lt;span style= "font-size: 10.0pt; line-height: 115%; font-family: 'Trebuchet MS',sans-serif; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt; In this week’s podcast, &lt;em&gt;Neurology Today&lt;/em&gt;’s editor-in-chief highlights articles on the potential of a new blood biomarker for ALS, a PACP-targeted migraine therapy, and a real-world review of data on eculizumab for neuromyelitis optica spectrum disorder.&lt;/span&gt;&lt;/p&gt; &lt;p&gt;&lt;span style= "font-size: 10.0pt; line-height: 115%; font-family: 'Trebuchet MS',sans-serif; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt; This Podcast is being Sponsored by LocumTenens.com&lt;/span&gt;&lt;/p&gt;</description>

Blood test for ALS, new migraine target reduces headache days, latest data on eculizumab for neuromyelitis optica spectrum disorder

In this week’s podcast, Neurology Today’s editor-in-chief highlights articles on the potential of a new blood biomarker for ALS, a PACP-targeted migraine therapy, and a real-world review of data on eculizumab for neuromyelitis optica spectrum disorder. This Podcast is being Sponsored by LocumTenens.com

Joseph E. Safdieh, MD, FAAN, Editor-in-Chief of Neurology Today highlights the most noteworthy and newsworthy neurology stories in the issue.

Neurology Today in 5

Details

Recent Episodes